IL181408A0 - 4-heteroarylmethyl substituted phthalazinone derivatives - Google Patents

4-heteroarylmethyl substituted phthalazinone derivatives

Info

Publication number
IL181408A0
IL181408A0 IL181408A IL18140807A IL181408A0 IL 181408 A0 IL181408 A0 IL 181408A0 IL 181408 A IL181408 A IL 181408A IL 18140807 A IL18140807 A IL 18140807A IL 181408 A0 IL181408 A0 IL 181408A0
Authority
IL
Israel
Prior art keywords
phthalazinone derivatives
heteroarylmethyl
heteroarylmethyl substituted
substituted phthalazinone
derivatives
Prior art date
Application number
IL181408A
Other languages
English (en)
Original Assignee
Maybridge Ltd
Javaid Muhammad Hashim
Smith Graeme Cameron Murray
Martin Niall Morrisson Barr
Gomez Sylvie
Loh Vincent Junior Ming Lai
Cockcroft Xiao Ling Fan
Forte Stefano
Menear Keith Allan
Matthews Ian Timothy William
Frank Kerrigan
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0419072.4A external-priority patent/GB0419072D0/en
Application filed by Maybridge Ltd, Javaid Muhammad Hashim, Smith Graeme Cameron Murray, Martin Niall Morrisson Barr, Gomez Sylvie, Loh Vincent Junior Ming Lai, Cockcroft Xiao Ling Fan, Forte Stefano, Menear Keith Allan, Matthews Ian Timothy William, Frank Kerrigan, Kudos Pharm Ltd filed Critical Maybridge Ltd
Publication of IL181408A0 publication Critical patent/IL181408A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL181408A 2004-08-26 2007-02-18 4-heteroarylmethyl substituted phthalazinone derivatives IL181408A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0419072.4A GB0419072D0 (en) 2004-08-26 2004-08-26 Phthalazinone derivatives
US60495604P 2004-08-27 2004-08-27
PCT/GB2005/003343 WO2006021801A1 (en) 2004-08-26 2005-08-26 4-heteroarylmethyl substituted phthalazinone derivatives

Publications (1)

Publication Number Publication Date
IL181408A0 true IL181408A0 (en) 2007-07-04

Family

ID=35219560

Family Applications (1)

Application Number Title Priority Date Filing Date
IL181408A IL181408A0 (en) 2004-08-26 2007-02-18 4-heteroarylmethyl substituted phthalazinone derivatives

Country Status (11)

Country Link
EP (1) EP1791827A1 (enrdf_load_stackoverflow)
JP (1) JP2008510783A (enrdf_load_stackoverflow)
KR (1) KR20070057859A (enrdf_load_stackoverflow)
AU (1) AU2005276229A1 (enrdf_load_stackoverflow)
BR (1) BRPI0514632A (enrdf_load_stackoverflow)
CA (1) CA2577191A1 (enrdf_load_stackoverflow)
IL (1) IL181408A0 (enrdf_load_stackoverflow)
MX (1) MX2007002318A (enrdf_load_stackoverflow)
NO (1) NO20071579L (enrdf_load_stackoverflow)
NZ (1) NZ553979A (enrdf_load_stackoverflow)
WO (1) WO2006021801A1 (enrdf_load_stackoverflow)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
US7834015B2 (en) 2006-05-31 2010-11-16 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-a] pyrazin-1(2H)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
GB0716532D0 (en) * 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2010002749A (es) * 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
MX2010005070A (es) 2007-11-15 2010-05-24 Angeletti P Ist Richerche Bio Derivados de piridazinona como inhibidores de parp.
AR070221A1 (es) * 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
PL2379525T3 (pl) 2008-12-19 2016-01-29 Centrexion Therapeutics Corp Cykliczne pirymidyno-4-karboksamidy jako antagoniści receptora CCR2 do leczenia stanów zapalnych, astmy oraz COPD
CA2782464C (en) 2009-12-17 2016-11-29 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
KR101242572B1 (ko) * 2010-10-12 2013-03-19 한국화학연구원 5-환 헤테로 아릴로 치환된 프탈라지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 약학적 조성물
EP2646428B1 (en) * 2010-12-02 2016-06-01 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivatives, preparation processes and medical uses thereof
JP5781636B2 (ja) * 2011-03-14 2015-09-24 インパクト セラピューティックス インコーポレイテッド キナゾリンジオン及びその使用
US20140221314A1 (en) 2011-05-31 2014-08-07 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102964354B (zh) * 2012-11-16 2014-08-13 江苏先声药业有限公司 一类噻吩并咪唑衍生物及其应用
CN102977040B (zh) * 2012-11-20 2015-06-03 浙江工业大学 一种2-喹喔啉基二甲缩醛和2-喹喔啉基甲醛的合成方法
WO2014102817A1 (en) 2012-12-31 2014-07-03 Cadila Healthcare Limited Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
HRP20191860T1 (hr) 2013-03-13 2019-12-27 Forma Therapeutics, Inc. Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka
CN106146492A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 杂环并咪唑类化合物、其药物组合物及其制备方法和用途
CN108026087B (zh) 2015-07-02 2021-06-04 中枢疗法公司 氨基嘧啶甲酮衍生物的柠檬酸盐
CN105384684B (zh) * 2015-12-16 2018-02-13 辽宁工程技术大学 一种2‑氰基‑6‑甲基吡啶的制备方法
US11542282B2 (en) 2018-02-28 2023-01-03 The Trustees Of The University Of Pennsylvania Low affinity poly(AD-ribose) polymerase 1 dependent cytotoxic agents
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
US20220110936A1 (en) * 2019-02-02 2022-04-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof
PH12022550098A1 (en) 2019-07-19 2022-11-21 Astrazeneca Ab Parp1 inhibitors
US20230234938A1 (en) 2020-04-28 2023-07-27 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA882639B (en) * 1987-05-02 1988-09-30 Asta-Pharma Aktiengesellschaft New 2-aminoalkyl-4-benzyl-1(2h)-phthalazinone derivatives
DE3813531A1 (de) * 1987-05-02 1988-11-10 Asta Pharma Ag Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate
CN1136197C (zh) * 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 新的哒嗪酮衍生物
BR0115062A (pt) * 2000-10-30 2004-02-17 Kudos Pharm Ltd Derivados de ftalazinona
GB0026505D0 (en) * 2000-10-30 2000-12-13 Kudos Pharm Ltd Phthalazinone derivatives
CA2444531A1 (en) * 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
JP3843454B2 (ja) * 2002-02-19 2006-11-08 小野薬品工業株式会社 縮合ピリダジン誘導体化合物およびその化合物を有効成分として含有する薬剤
DE60335359D1 (de) * 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
KR101146806B1 (ko) * 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체

Also Published As

Publication number Publication date
BRPI0514632A (pt) 2008-06-17
JP2008510783A (ja) 2008-04-10
KR20070057859A (ko) 2007-06-07
EP1791827A1 (en) 2007-06-06
AU2005276229A1 (en) 2006-03-02
NO20071579L (no) 2007-05-29
MX2007002318A (es) 2007-04-17
NZ553979A (en) 2009-05-31
WO2006021801A1 (en) 2006-03-02
CA2577191A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
ZA200702479B (en) 4-heteroarylmethyl substituted phthalazinone derivatives
IL181408A0 (en) 4-heteroarylmethyl substituted phthalazinone derivatives
GB2415430B (en) Phthalazinone derivatives
IL180481A0 (en) Aryl-pyridine derivatives
IL177968A0 (en) Tetrahydropyridoindole derivatives
IL179736A0 (en) Pyrrazolo-pyrimidine derivatives
IL182094A0 (en) Quinazoline derivatives
IL179484A0 (en) New 4-benzylidene-piperidin derivatives
IL183140A0 (en) Substituted benzoquinolizine derivatives
IL182585A0 (en) Imidazo-benzodiazepine derivatives
IL183142A0 (en) New pyridothienopyrimidine derivatives
GB0428111D0 (en) Pthalazinone derivatives
IL179444A0 (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
IL183141A0 (en) New pyridothienopyrimidine derivatives
EP1810965A4 (en) HYDRAZIDE DERIVATIVES
GB0414272D0 (en) OsK1 derivatives
TWI346109B (en) 4-amino-5-cyanopyrimidine derivatives
IL182001A0 (en) 2-acylaminothiazole derivatives
ZA200804193B (en) 4-heteroarymethyl substituted phthalazinone derivatives
IL190893A0 (en) 4-heteroarymethyl substituted phthalazinone derivatives
HK1100390A (en) 4-heteroarylmethyl substituted phthalazinone derivatives
HK1113679A (en) 4-heteroarymethyl substituted phthalazinone derivatives
GB0405905D0 (en) Azaquinazoline derivatives
GB0422397D0 (en) 3-Cyano-Quinoline derivatives
GB0426653D0 (en) Quinazoline derivatives